FPFernanda Maris Peria

Fernanda Maris Peria

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Fernanda Maris Peria has a total of 141 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Real-world disparities in molecular diagnosis of diffuse gliomas in Brazil: Insights from LACOG 0619

    by Camilla Akemi Felizardo Yamada, Marcos Vinicius Calfat Maldaun, Fabiana Spilari Viola, Clarissa Baldotto, Fernando C Maluf, Vanessa Montes Santos, Carolina Fittipaldi Pessoa, Daniela Barros, Fernanda Maris Peria, Patrícia Pacheco, et al.

    Background: Diffuse gliomas in adults are rare, aggressive central nervous system (CNS) tumors whose outcomes are strongly influenced by molecular features. In Brazil, data on epidemiology, molecular diagnostics, and survival are scarce, particularly following the WHO CNS 2021 classification. The LACOG 0619 RWD (Real-World Data) addresses this gap by characterizing Brazilian diffuse glioma patients and evaluating diagnostic disparities. Methods: This retrospective, multicenter cohort included adults (≥18 years) with histologically confirmed diffuse gliomas from 9 centers in Brazil (2010-2019). Reclassification followed WHO CNS 2021 criteria. Completeness of molecular workup was compared between public and private institutions. Results: A total of 828 patients were included (median age 52 years, 56.0% male, 57.6% from private centers). Glioblastoma was the most frequent histology (57%). The central finding was a marked disparity in access to molecular diagnostics: IDH (Isocitrate Dehydrogenase), 1p/19q, MGMT (O6-Methylguanine-DNA Methyltransferase), and Next-Generation Sequencing testing were far more frequent in private institutions. Although testing rates improved after 2016, <20% of eligible cases underwent IDH sequencing. Survival differed by histology and WHO 2021 criteria, with 5-year overall survival ranging from 20.2% in IDH-wildtype glioblastoma to 90.9% in IDH-mutant grade 2 gliomas (P < .001), confirming the prognostic impact of molecular testing. Conclusions: LACOG 0619 is the first and largest RWD to assess molecular diagnostic gaps in diffuse gliomas in Brazil. The study reveals profound inequities between public and private healthcare institutions, underscoring the urgent need to expand equitable access to molecular testing as an essential step toward enhancing patient care and ensuring inclusion in precision oncology.


  • Open Access

    Incident safety reports on generic and branded docetaxel medications in a teaching hospital

    by Luiz Henrique Rialto, Lara Riboli-Bortolato, Vinícius DE Paula-Pereira, Fernanda Maris-Peria, Laura Martins-Valdevite, Maria Olívia Barboza-Zanetti, Giovanna Rossi-Varallo, João Paulo Vilela-Rodrigues, Leonardo Régis Leira-Pereira, Fabiana Rossi-Varallo

    Objective: To compare incident reporting associated with generic and branded docetaxel in a Brazilian teaching hospital, and to analyze the pharmacovigilance notifications involving this drug in a teaching hospital. Methods: A cross-sectional study was conducted in a high complexity Brazilian university hospital. Data from patients aged 18 years or older were included. Incidents associated with docetaxel 80 mg reported in the hospital’s pharmacovigilance database from January 1st, 2018, to December 31st, 2020, were analyzed. Reports of adverse drug reactions (ADR), therapeutic ineffectiveness, medication errors, and quality deviations (QD) were considered. Additionally, the underreporting rate of late ADRs was calculated. For descriptive analysis it was used the number of cases and percentages for categorical variables; and mean and standard deviation (SD) for continuous variables. Results: 124 incident reports related to chemotherapeutic agents were recorded. Among these, 34 (27.4%) were associated with docetaxel. Two involved the generic medication, while 32 were associated with the branded medication. Despite having a well-established multidisciplinary team in the oncology department, the most frequent reporters were nurses (26/34). The reports described 35 incidents: 21 ADR (10 immediate and 11 delayed) and 14 QD. Nine immediate ADR, 11 delayed ADR, and 12 QD reports were related to branded medication. The underreporting rate was 93.0%. Conclusion: Underreporting hindered the comparison of incidentes associated with generic and branded docetaxel in the pharmacovigilance database. The lack of medication safety communication decreases signal detection and compromises decision-making rely on real-world data. In this regard, the findings suggest the need for educational interventions for healthcare professionals to improve attitudes towards pharmacovigilance.

  • The need for alternative exercise interventions to enhance physical function and emotional well-being of patients during colorectal cancer treatment

    by Rafael Akira Fujita, Fernanda Maris Peria, Kristin Leigh Campbell, Mucio Luis de Assis Cirino, Marina Mello Villalba, Daniela Pretti da Cunha Tirapelli, Matheus Machado Gomes

  • Open Access

    Filling gaps in experiences religious understanding of people living with cancer in palliative care: a phenomenological qualitative study

    by Hellen Luiza Meireles Silva, Pedro Henrique Martins Valério, Cristiano Roque Antunes Barreira, Fernanda Maris Peria

    Background: According to a phenomenology of contemporary religion, the analysis of religious experiences finds that they are part of an individual’s search for something powerful that overcomes him seeking not only a need, but the meaning of all existence. The present study aims to contribute to a deeper understanding of the religious experiences of people living with cancer in palliative care (PC) and fill gaps in access to experience, with regard to how it was properly lived. Methods: A qualitative, phenomenological, cross-sectional study was conducted with 14 people living with cancer undergoing PC at two outpatient clinics of a public hospital. The experiences were accessed through in-depth interviews and the results were analysed according to the principles of classical phenomenology. Results: The patients confidently surrendered to the divine, attributing to it the power of continuity of life or not, which sustained them and launched them into horizons of hope, directing them to possibilities of achieving meaning in life, which it fed back their faith and to continue living, opening them up to an intense perception of the value of life. Conclusions: The religious positions of confident surrender to the divine, to his will and a belief in his intervention, regardless of the outcome, opened possibilities to patients for the belief in the continuity of life by the power of faith. This position allowed the patients in this study to visualize achievements in the present and in the future, opening a horizon of hope, meaning and value of living. This study showed how this elements are presented and sustained, providing subsidies to health professionals seeking to provide more holistic care.


  • Open Access

    Radiotherapy for Brain Metastases Near the End of Life: Characterizing Patients and Tumor Features

    by Saulo Brito Silva, Rafael Balsini Barreto, Fernanda Cristina Gonçalves de Oliveira, Gabriela Schmidt Defende Martin, Ofelia Maria Yukie Takiguchi, Iasmin Alves Chirichela, Mário Henrique Furlanetto Miranda, Denize Bodnar, Luiz Augusto Alves Reis, Gabriel Clemente Brito Pereira, et al.

    PURPOSE: Patients with brain metastases are often referred for brain radiotherapy (BrRT) when exclusive palliative management would be more appropriate. To assess the indication of BrRT during end-of-life (EOL) care and evaluate the characteristics of the patients who underwent the treatment. METHODS: This retrospective study comprised patients from four independent oncology centers who had undergone BrRT for metastases. The variables included were Karnofsky performance status (KPS), primary tumor site, metastatic status, neurologic symptomatic status, the number and size of metastases, posterior fossa or meningeal involvement, type of BrRT, having undergone brain metastasectomy, and the availability of systemic therapies after BrRT. Patients were allocated into three subgroups with ≤30, 31-60, and 61-90 days of survival, and a control group of patients who survived >90 days. RESULTS: A total of 546 patients were included in the study. A KPS of 90 days. CONCLUSION: Considering patients' performance status and whether they are candidates for brain metastasectomy or systemic therapies after BrRT is critical to improving BrRT benefits in scenarios of EOL.


  • Open Access

    Mirtazapine versus Megestrol in the Treatment of Anorexia–Cachexia Syndrome in Patients with Advanced Cancer: A Randomized, Double-Blind, Controlled Phase II Clinical Trial

    by Olga Laura Sena Almeida, Eduardo Ferriolli, Roberta Cristina Cintra Taveira, Meire Gallo Rosenburg, Daniela Dalpubel Campanari, Natália Maira da Cruz Alves, Karina Pfrimer, Liane Rapatoni, Fernanda Maris Peria, Nereida K. C. Lima

    This study compared mirtazapine with megestrol in the management of cancer-related anorexia–cachexia syndrome in patients with advanced cancer. A randomized, double-blind, controlled clinical trial involving patients with advanced cancer and anorexia–cachexia syndrome was performed. Participants received mirtazapine 30 mg/day or megestrol 320 mg/day for eight weeks. The primary endpoint was the effect of mirtazapine on weight gain and the secondary endpoints were its effect on appetite, muscle strength, physical performance, body composition, adverse events, and medication adherence. Linear regression model with mixed effects was applied and a significance level of 5% was adopted. Fifty-two patients were randomized. Mean age was 65.8 ± 8.4 years. There was weight gain in 52% of the participants in the megestrol group and in 38% in the mirtazapine group after four weeks (p = 0.040). Appetite improved in 92% of the participants in the megestrol group and in 56% in the mirtazapine group after eight weeks (p = 0.007). In the sub-analysis by sex, women showed improvement in appetite (p < 0.001) and weight gain (p < 0.005) in the mirtazapine group, which was not observed in men. Mirtazapine appears to be inferior to megestrol in weight and appetite improvement. However, there may be a difference in the therapeutic response between sexes.


  • Open Access

    Modulation of Genes and MicroRNAs in the Neurospheres of Glioblastoma Cell Lines U343 and T98G Induced by Ionizing Radiation and Temozolomide Therapy

    by Thiago L. Da Costa Almeida, Andressa R. Rodrigues, Múcio Cirino, Felipe A Trevisan, Fernanda Peria, Daniela Tirapelli, Carlos Gilberto Carlotti Jr

    Introduction: Glioblastoma is the most prevalent primary malignant neoplasm of the central nervous system. It has increased its incidence, while the overall survival remains over 14 months. Purpose: The purpose is to evaluate the expression of the genes EGFR, PTEN, MGMT, and IDH1/2, and microRNAs miR-181b, miR-145, miR-149, and miR-128a in adhered cells (AC) and neurospheres (NS) from cell lines (T98G and U343) submitted to temozolomide (TMZ) and ionizing radiation (IR). Methods: T98G and U343 were treated with TMZ, IR, and TMZ+IR. The analysis of gene expression and miRNAs was performed using real-time PCR. Results: This study demonstrated: a) an improvement in the expression of IDH1 after IR and TMZ + IR in the NS (T98G); b) an increase in the expression of MGMT in NS (T98G) in IR groups and TMZ + IR. The expression of miRNAs results as a) AC (U343) expressed more miR-181b after TMZ, IR, and TMZ + IR; and miR-128a improved after TMZ, IR, and TMZ + IR; b) NS (T98G) after TMZ + IR expressed: miR-181b; miR-149; miR-145 and miR-128a; c) NS (U343) after IR huge expressed miR-149 and miR-145. Conclusion: IR was an independent and determining radioresistance factor in NS. However, we observed no complementarity action of oncomiRs regulation.

  • Apoptosis related microRNAs and MGMT in glioblastoma cell lines submitted to treatments with ionizing radiation and temozolomide

    by Felipe Amstalden Trevisan, Andressa Romualdo Rodrigues, Fermino Sanches Lizarte Neto, Fernanda Maris Peria, Múcio Luiz de Assis Cirino, Daniela Pretti da Cunha Tirapelli, Carlos Gilberto Carlotti Júnior

    Aim: To evaluate the effect of radiotherapy and temozolomide on the expression of miRNAs apoptotic (miRNAs-21, -221, -222 (anti-apoptotic) and miRNAs-15a, -16 (pro-apoptotic)) and the gene MGMT in glioblastoma cell lines. Background: The limited knowledge of the molecular biology of malignant gliomas may hinder the development of therapeutic modalities. In this scenario, one of the greatest advances of recent years was the identification of microRNAs. These molecules have an important role in biological processes involving cancer, including glioblastoma. Materials and methods Trypan blue was used to verify the cell viability, and real time PCR to quantify the expression of microRNAs and gene 24, 48 and 120 h after exposure to treatments. Results: There was a statistically significant decrease of expression of miR-15a between 48 and 120 h in line T98 G treated with radiation, increased expression of miR-15a between 24 and 120 h in line U251 treated with radiation and temozolomide, and increased expression of miR-16 between 24 and 120 h in line U251 treated with radiation alone and when combined with temozolomide. There was a decrease in MGMT gene expression, between 24 and 48 h in U343 cells treated with temozolomide. Conclusions: Ionizing radiation and temozolomide modified the expression of miRNAs studied and MGMT.


  • Open Access

    Weight Gain during Systemic Oncologic Therapy for Breast Cancer: Changes in Food Intake and Physical Activity

    by Marco Aurélio da Silva Ribeiro-Sousah, Isabelle Mastelaro, Fernanda Maris Peria, Hélio Angotti Carrara, Jurandyr Moreira de Andrade, Selma Freire de Carvalho Cunha

    Introduction: Weight gain frequently occurs during treatment for breast cancer. Objective: To evaluate changes in dietary intake and physical activity in the weight evolution of women on systemic oncologic treatment for breast cancer. Method: The prospective and comparative study included 89 women submitted to systemic oncologic treatment for breast cancer, grouped according to the occurrence of weight gain in relation to body weight documented before beginning treatment. Patients were classified as 1) Group with weight gain (those with an increase in body weight greater than or equal to 2% over pre-treatment weight); 2) Group without weight gain (those who maintained or lost weight during treatment). We calculated body mass index (BMI) of patients and analyzed their body composition by bioelectrical impedance (BIA). Changes in food intake, gastrointestinal symptoms, and physical activity level, as well as reductions in muscle and fat mass, were documented. Results: Tumor staging (p=0.24), use of antineoplastic drugs (p=0.23) and intention of treatment (p=0.61) were no different between the weight gain group (n=36) and no weight gain group (n=53). No difference was found in anthropometric and BIA data between the groups during oncologic treatment. Frequency of gastrointestinal symptoms was not different between the groups. However, increased food intake and bed rest, and a decrease in physical activity level were more frequent among women who gained weight during therapy. Conclusions: Weight gain in women undergoing systemic oncologic therapy for breast cancer may be, at least in part, caused by higher energy intake and lower physical activity.


  • MiRNA-133a underexpressed in patients with non-hereditary colon cancer

    by M. Bernardes, R.S. Parra, M.R. Feitosa, F.M. Peria, D.P.D.C. Tirapelli, J.J.R. Rocha, O. Feres